Woodstock Corp Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Woodstock Corp increased its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 2.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 134,130 shares of the biopharmaceutical company’s stock after buying an additional 2,575 shares during the period. Woodstock Corp’s holdings in Pfizer were worth $6,873,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in PFE. Karp Capital Management Corp acquired a new stake in Pfizer during the 3rd quarter worth $27,000. Worth Asset Management LLC acquired a new position in Pfizer in the first quarter valued at $29,000. Delos Wealth Advisors LLC increased its stake in Pfizer by 100.0% in the third quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 400 shares during the period. Legend Financial Advisors Inc. acquired a new position in Pfizer in the third quarter valued at $42,000. Finally, Align Wealth Management LLC acquired a new position in Pfizer in the fourth quarter valued at $45,000. Hedge funds and other institutional investors own 67.62% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $40.10 on Friday. The company has a 50-day moving average of $43.26 and a two-hundred day moving average of $46.03. The company has a current ratio of 1.22, a quick ratio of 1.00 and a debt-to-equity ratio of 0.34. The stock has a market cap of $225.33 billion, a P/E ratio of 7.32, a PEG ratio of 1.33 and a beta of 0.64. Pfizer Inc. has a 12-month low of $39.23 and a 12-month high of $56.32.

Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.11. The business had revenue of $24.30 billion during the quarter, compared to analyst estimates of $24.40 billion. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The company’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.08 earnings per share. As a group, research analysts predict that Pfizer Inc. will post 3.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on PFE shares. Wells Fargo & Company dropped their price objective on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Friday. Bank of America downgraded shares of Pfizer from a “buy” rating to a “neutral” rating and set a $60.00 target price on the stock. in a report on Wednesday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $75.00 target price on shares of Pfizer in a report on Wednesday, February 1st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and set a $51.00 target price on the stock in a report on Tuesday, February 7th. Finally, Credit Suisse Group lowered their target price on shares of Pfizer from $54.00 to $50.00 and set an “outperform” rating on the stock in a report on Wednesday, February 1st. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $50.38.

Pfizer Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.